James C Mullen - Net Worth and Insider Trading

James C Mullen Net Worth

The estimated net worth of James C Mullen is at least $30 Million dollars as of 2024-11-06. James C Mullen is the CEO & President of Biogen Inc and owns about 131,149 shares of Biogen Inc (BIIB) stock worth over $23 Million. James C Mullen is the Director of Revvity Inc and owns about 45,551 shares of Revvity Inc (RVTY) stock worth over $6 Million. James C Mullen is also the Director of Insulet Corp and owns about 5,598 shares of Insulet Corp (PODD) stock worth over $1 Million. Besides these, James C Mullen also holds Editas Medicine Inc (EDIT) . Details can be seen in James C Mullen's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that James C Mullen has not made any transactions after 2021-10-18 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of James C Mullen

James C Mullen Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, James C Mullen owns 6 companies in total, including Editas Medicine Inc (EDIT) , Thermo Fisher Scientific Inc (TMO) , and Insulet Corp (PODD) among others .

Click here to see the complete history of James C Mullen’s form 4 insider trades.

Insider Ownership Summary of James C Mullen

Ticker	Comapny	Transaction Date	Type of Owner
EDIT	Editas Medicine Inc	2021-10-18	director
TMO	Thermo Fisher Scientific Inc	2018-11-07	director
PODD	Insulet Corp	2017-11-13	director
		2017-08-29	director & Chief Executive Officer
		2014-11-14	director
		2010-03-22	director & CEO & President

James C Mullen Latest Holdings Summary

James C Mullen currently owns a total of 4 stocks. Among these stocks, James C Mullen owns 131,149 shares of Biogen Inc (BIIB) as of March 22, 2010, with a value of $23 Million and a weighting of 76.15%. James C Mullen owns 45,551 shares of Revvity Inc (RVTY) as of November 14, 2014, with a value of $6 Million and a weighting of 18.83%. James C Mullen also owns 5,598 shares of Insulet Corp (PODD) as of November 13, 2017, with a value of $1 Million and a weighting of 4.43%. The other 1 stocks Editas Medicine Inc (EDIT) have a combined weighting of 0.59% among all his current holdings.

Latest Holdings of James C Mullen

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
BIIB	Biogen Inc	2010-03-22	131,149	176.93	23,204,193
RVTY	Revvity Inc	2014-11-14	45,551	125.96	5,737,604
PODD	Insulet Corp	2017-11-13	5,598	241.32	1,350,909
EDIT	Editas Medicine Inc	2021-10-18	57,673	3.12	179,940

Holding Weightings of James C Mullen

James C Mullen Form 4 Trading Tracker

According to the SEC Form 4 filings, James C Mullen has made a total of 0 transactions in Biogen Inc (BIIB) over the past 5 years. The most-recent trade in Biogen Inc is the sale of 440,500 shares on March 22, 2010, which brought James C Mullen around $26 Million.

According to the SEC Form 4 filings, James C Mullen has made a total of 0 transactions in Revvity Inc (RVTY) over the past 5 years. The most-recent trade in Revvity Inc is the sale of 8,892 shares on November 14, 2014, which brought James C Mullen around $388,847.

According to the SEC Form 4 filings, James C Mullen has made a total of 0 transactions in Insulet Corp (PODD) over the past 5 years. The most-recent trade in Insulet Corp is the acquisition of 2,500 shares on November 13, 2017, which cost James C Mullen around $168,625.

More details on James C Mullen's insider transactions can be found in the Insider Trading History of James C Mullen table.

Insider Trading History of James C Mullen

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

James C Mullen Trading Performance

GuruFocus tracks the stock performance after each of James C Mullen's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by James C Mullen is -10.89%. GuruFocus also compares James C Mullen's trading performance to market benchmark return within the same time period. The performance of stocks bought by James C Mullen within 3 months outperforms 1 times out of 4 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how James C Mullen's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of James C Mullen

Average Return

Average return per transaction

Outperforming Transactions

2 out of 4 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	4.04
Relative Return to S&P 500(%)	1.09

James C Mullen Ownership Network

Ownership Network List of James C Mullen

No Data

Ownership Network Relation of James C Mullen

James C Mullen Owned Company Details

What does Editas Medicine Inc do?

Who are the key executives at Editas Medicine Inc?

James C Mullen is the director of Editas Medicine Inc. Other key executives at Editas Medicine Inc include SVP & CHIEF MEDICAL OFFICER Baisong Mei , director & CEO Gilmore Neil O'neill , and EVP & CHIEF SCIENTIFIC OFFICER Linda Burkly .

Editas Medicine Inc (EDIT) Insider Trades Summary

Over the past 18 months, James C Mullen made no insider transaction in Editas Medicine Inc (EDIT). Other recent insider transactions involving Editas Medicine Inc (EDIT) include a net sale of 2,791 shares made by Bruce Eaton , a net sale of 32,292 shares made by Baisong Mei , and a net sale of 98,056 shares made by Gilmore Neil O'neill .

In summary, during the past 3 months, insiders sold 2,073 shares of Editas Medicine Inc (EDIT) in total and bought 0 shares, with a net sale of 2,073 shares. During the past 18 months, 168,311 shares of Editas Medicine Inc (EDIT) were sold and 45,000 shares were bought by its insiders, resulting in a net sale of 123,311 shares.

Editas Medicine Inc (EDIT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Editas Medicine Inc Insider Transactions

No Available Data

What does Thermo Fisher Scientific Inc do?

Who are the key executives at Thermo Fisher Scientific Inc?

James C Mullen is the director of Thermo Fisher Scientific Inc. Other key executives at Thermo Fisher Scientific Inc include Senior Vice President Marc N Casper , Sr. VP and Gen. Counsel Michael A Boxer , and Executive Vice President Gianluca Pettiti .

Thermo Fisher Scientific Inc (TMO) Insider Trades Summary

Over the past 18 months, James C Mullen made no insider transaction in Thermo Fisher Scientific Inc (TMO). Other recent insider transactions involving Thermo Fisher Scientific Inc (TMO) include a net sale of 292,497 shares made by Marc N Casper , a net sale of 20,562 shares made by Michael A Boxer , and a net sale of 3,600 shares made by Gianluca Pettiti .

In summary, during the past 3 months, insiders sold 68,150 shares of Thermo Fisher Scientific Inc (TMO) in total and bought 0 shares, with a net sale of 68,150 shares. During the past 18 months, 406,681 shares of Thermo Fisher Scientific Inc (TMO) were sold and 4 shares were bought by its insiders, resulting in a net sale of 406,677 shares.

Thermo Fisher Scientific Inc (TMO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Thermo Fisher Scientific Inc Insider Transactions

No Available Data

What does Insulet Corp do?

Who are the key executives at Insulet Corp?

James C Mullen is the director of Insulet Corp. Other key executives at Insulet Corp include SVP & Chief Technology Officer Mark N Field , VP & CAO and Controller Lauren Budden , and SVP & Global Operations Prem Singh .

Insulet Corp (PODD) Insider Trades Summary

Over the past 18 months, James C Mullen made no insider transaction in Insulet Corp (PODD). Other recent insider transactions involving Insulet Corp (PODD) include a net sale of 6,401 shares made by Mark N Field , a net sale of 15,300 shares made by Timothy J Scannell , and a net sale of 932 shares made by Luciana Borio .

In summary, during the past 3 months, insiders sold 18,728 shares of Insulet Corp (PODD) in total and bought 100 shares, with a net sale of 18,628 shares. During the past 18 months, 81,763 shares of Insulet Corp (PODD) were sold and 8,951 shares were bought by its insiders, resulting in a net sale of 72,812 shares.

Insulet Corp (PODD)'s detailed insider trading history can be found in Insider Trading Tracker table.

Insulet Corp Insider Transactions

No Available Data

What does Patheon NV do?

Who are the key executives at Patheon NV?

James C Mullen is the director & Chief Executive Officer of Patheon NV. Other key executives at Patheon NV include EVP and Chief Talent Officer Craig Eric Schneier , General Counsel and Secretary Eric Sherbet , and President Michel Lagarde .

Patheon NV (PTHN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Patheon NV (PTHN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Patheon NV (PTHN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Patheon NV (PTHN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Patheon NV Insider Transactions

No Available Data

What does Revvity Inc do?

Who are the key executives at Revvity Inc?

James C Mullen is the director of Revvity Inc. Other key executives at Revvity Inc include Please See Remarks Tajinder Vohra , See Remarks Joel S Goldberg , and Please See Remarks Prahlad R. Singh .

Revvity Inc (RVTY) Insider Trades Summary

Over the past 18 months, James C Mullen made no insider transaction in Revvity Inc (RVTY). Other recent insider transactions involving Revvity Inc (RVTY) include a net sale of 23,810 shares made by Joel S Goldberg , a net sale of 14,379 shares made by Tajinder Vohra , and a net sale of 22,361 shares made by Prahlad R. Singh .

In summary, during the past 3 months, insiders sold 10,811 shares of Revvity Inc (RVTY) in total and bought 0 shares, with a net sale of 10,811 shares. During the past 18 months, 61,400 shares of Revvity Inc (RVTY) were sold and 0 shares were bought by its insiders, resulting in a net sale of 61,400 shares.

Revvity Inc (RVTY)'s detailed insider trading history can be found in Insider Trading Tracker table.

Revvity Inc Insider Transactions

No Available Data

What does Biogen Inc do?

Who are the key executives at Biogen Inc?

James C Mullen is the director & CEO & President of Biogen Inc. Other key executives at Biogen Inc include Head of Development Priya Singhal , Head of Research Jane Grogan , and EVP & Human Resources Ginger Gregory .

Biogen Inc (BIIB) Insider Trades Summary

Over the past 18 months, James C Mullen made no insider transaction in Biogen Inc (BIIB). Other recent insider transactions involving Biogen Inc (BIIB) include a net sale of 2,569 shares made by Priya Singhal , and a net purchase of 455 shares made by Eric K Rowinsky .

In summary, during the past 3 months, insiders sold 431 shares of Biogen Inc (BIIB) in total and bought 0 shares, with a net sale of 431 shares. During the past 18 months, 2,569 shares of Biogen Inc (BIIB) were sold and 455 shares were bought by its insiders, resulting in a net sale of 2,114 shares.

Biogen Inc (BIIB)'s detailed insider trading history can be found in Insider Trading Tracker table.

Biogen Inc Insider Transactions

No Available Data

James C Mullen Mailing Address

Above is the net worth, insider trading, and ownership report for James C Mullen. You might contact James C Mullen via mailing address: 940 Winter Street, Perkinelmer, Inc Legal Department, Waltham Ma 02451.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.